Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advaxis, Merck to combine immunotherapies for prostate cancer

This article was originally published in Scrip

Executive Summary

Advaxis jumped 23.1% to $4 per share on 25 August after the company announced a second partnership to test its immunotherapy platform in combination with a programmed cell death-1 (PD-1) inhibitor, the Merck & Co biologic pembrolizumab (MK-3475).

Advertisement

Related Content

Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel